One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Incyte cleared that benchmark Thursday, with a jump from 76 to 81 Thursday.
This exclusive rating from Investor's Business Daily measures market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the trailing 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history reveals that the best stocks typically have an 80 or higher RS Rating as they begin their biggest price moves.
Hone Your Stock-Picking Skills By Focusing On These Factors
Incyte is now considered extended and out of buy range after clearing a 70.36 buy point in a first-stage flat base. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
Earnings-per-share growth fell last quarter from 0% to -3%, but revenue rose from 9% to 24%.
The company holds the No. 57 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Corcept Therapeutics and Catalyst Pharmaceuticals are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
